Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Accured Expenses (2016 - 2025)

China Pharma Holdings' Change in Accured Expenses history spans 16 years, with the latest figure at $432777.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 40.64% year-over-year to $432777.0; the TTM value through Dec 2025 reached $465753.0, up 8.01%, while the annual FY2025 figure was $465753.0, 8.01% up from the prior year.
  • Change in Accured Expenses reached $432777.0 in Q4 2025 per CPHI's latest filing, up from -$68702.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $804339.0 in Q4 2022 to a low of -$450887.0 in Q1 2023.
  • Average Change in Accured Expenses over 5 years is $113112.2, with a median of $83626.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: crashed 579.2% in 2022, then surged 940.44% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $207099.0 in 2021, then surged by 288.38% to $804339.0 in 2022, then crashed by 47.67% to $420886.0 in 2023, then skyrocketed by 73.24% to $729131.0 in 2024, then tumbled by 40.64% to $432777.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Change in Accured Expenses are $432777.0 (Q4 2025), -$68702.0 (Q3 2025), and $187274.0 (Q2 2025).